BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

657 related articles for article (PubMed ID: 11156381)

  • 21. A single nucleotide polymorphism in the 3'untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare.
    Kumar R; Smeds J; Berggren P; Straume O; Rozell BL; Akslen LA; Hemminki K
    Int J Cancer; 2001 Nov; 95(6):388-93. PubMed ID: 11668523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Germline mutations in CDKN2A are infrequent in female patients with melanoma and breast cancer.
    Nagore E; Montoro A; García-Casado Z; Botella-Estrada R; Insa A; Lluch A; López-Guerrero JA; Guillén C
    Melanoma Res; 2009 Aug; 19(4):211-4. PubMed ID: 19571771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.
    Kannengiesser C; Brookes S; del Arroyo AG; Pham D; Bombled J; Barrois M; Mauffret O; Avril MF; Chompret A; Lenoir GM; Sarasin A; ; Peters G; Bressac-de Paillerets B
    Hum Mutat; 2009 Apr; 30(4):564-74. PubMed ID: 19260062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple primary melanoma revisited.
    Blackwood MA; Holmes R; Synnestvedt M; Young M; George C; Yang H; Elder DE; Schuchter LM; Guerry D; Ganguly A
    Cancer; 2002 Apr; 94(8):2248-55. PubMed ID: 12001124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First detection of the melanoma-predisposing proline-48-threonine mutation of p16 in Hungarians: was there a common founder either in Italy or in Hungary?
    Széll M; Balogh K; Dobozy A; Kemény L; Oláh J
    Melanoma Res; 2007 Aug; 17(4):251-4. PubMed ID: 17625456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study.
    Berwick M; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Kanetsky PA; Busam K; From L; Mujumdar U; Wilcox H; Begg CB;
    Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1520-5. PubMed ID: 16896043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Swedish CDKN2A mutation carriers do not present the atypical mole syndrome phenotype.
    Nielsen K; Harbst K; Måsbäck A; Jönsson G; Borg A; Olsson H; Ingvar C
    Melanoma Res; 2010 Aug; 20(4):266-72. PubMed ID: 20526219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CDKN2A as a uveal and cutaneous melanoma susceptibility gene.
    Kannengiesser C; Avril MF; Spatz A; Laud K; Lenoir GM; Bressac-de-Paillerets B
    Genes Chromosomes Cancer; 2003 Nov; 38(3):265-8. PubMed ID: 14506702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of Latvian familial melanoma patients shows novel variants in the noncoding regions of CDKN2A and that the CDK4 mutation R24H is a founder mutation.
    Veinalde R; Ozola A; Azarjana K; Molven A; Akslen LA; Doniņa S; Proboka G; Cēma I; Baginskis A; Pjanova D
    Melanoma Res; 2013 Jun; 23(3):221-6. PubMed ID: 23546221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma.
    Platz A; Hansson J; Månsson-Brahme E; Lagerlof B; Linder S; Lundqvist E; Sevigny P; Inganäs M; Ringborg U
    J Natl Cancer Inst; 1997 May; 89(10):697-702. PubMed ID: 9168184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New founder germline mutations of CDKN2A in melanoma-prone families and multiple primary melanoma development in a patient receiving levodopa treatment.
    Kannengiesser C; Dalle S; Leccia MT; Avril MF; Bonadona V; Chompret A; Lasset C; Leroux D; Thomas L; Lesueur F; Lenoir G; Sarasin A; Bressac-de Paillerets B
    Genes Chromosomes Cancer; 2007 Aug; 46(8):751-60. PubMed ID: 17492760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel CDKN2A mutation detected in Spanish melanoma pedigree.
    de Torre C; Martínez-Escribano J
    Exp Dermatol; 2010 Aug; 19(8):e333-5. PubMed ID: 20653773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [From gene to disease; from p16 to melanoma].
    Gruis NA; Bergman W
    Ned Tijdschr Geneeskd; 2000 Oct; 144(44):2100-2. PubMed ID: 11103670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutation analysis of the CDKN2A promoter in Australian melanoma families.
    Pollock PM; Stark MS; Palmer JM; Walters MK; Aitken JF; Martin NG; Hayward NK
    Genes Chromosomes Cancer; 2001 Sep; 32(1):89-94. PubMed ID: 11477665
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma.
    Ohta M; Nagai H; Shimizu M; Rasio D; Berd D; Mastrangelo M; Singh AD; Shields JA; Shields CL; Croce CM
    Cancer Res; 1994 Oct; 54(20):5269-72. PubMed ID: 7923152
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of variations in melanoma susceptibility genes among Slovenian melanoma families.
    Peric B; Cerkovnik P; Novakovic S; Zgajnar J; Besic N; Hocevar M
    BMC Med Genet; 2008 Sep; 9():86. PubMed ID: 18803811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Indication for CDKN2A-mutation analysis in familial pancreatic cancer families without melanomas.
    Harinck F; Kluijt I; van der Stoep N; Oldenburg RA; Wagner A; Aalfs CM; Sijmons RH; Poley JW; Kuipers EJ; Fockens P; van Os TA; Bruno MJ
    J Med Genet; 2012 Jun; 49(6):362-5. PubMed ID: 22636603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family.
    Maubec E; Chaudru V; Mohamdi H; Blondel C; Margaritte-Jeannin P; Forget S; Corda E; Boitier F; Dalle S; Vabres P; Perrot JL; Lyonnet DS; Zattara H; Mansard S; Grange F; Leccia MT; Vincent-Fetita L; Martin L; Crickx B; Joly P; Thomas L; ; Bressac-de Paillerets B; Avril MF; Demenais F
    J Am Acad Dermatol; 2012 Dec; 67(6):1257-64. PubMed ID: 22841127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of mutations in the p16/CDKN2A gene in sporadic and familial melanoma in the Polish population.
    Lamperska K; Karezewska A; Kwiatkowska E; Mackiewicz A
    Acta Biochim Pol; 2002; 49(2):369-76. PubMed ID: 12362978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CDKN2A mutation and deletion status in thin and thick primary melanoma.
    Cachia AR; Indsto JO; McLaren KM; Mann GJ; Arends MJ
    Clin Cancer Res; 2000 Sep; 6(9):3511-5. PubMed ID: 10999737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.